ChondroGene Inc.'s Dr. Daniel H. Farkas Chairs And Opens American Association for Clinical Chemistry Annual Meeting
Published: Jul 21, 2006
TORONTO, July 21 /PRNewswire-FirstCall/ - ChondroGene Limited announced today that Dr. Daniel H. Farkas, PhD, HCLD, will officially open the 58th Annual Meeting of the American Association of Clinical Chemistry (AACC) being held in Chicago from July 23 to 27. Dr. Farkas was appointed Chair, AACC Annual Meeting Organizing Committee (AMOC) in 2004 and was instrumental in identifying and selecting speakers and programs for the event. Dr. Farkas will officially open the meeting on Sunday July 23 and introduce the President of the AACC. He will also introduce each day's plenary speaker, moderate several 'Meet the Experts' sessions and act as chairman for two of the 'Invited Sessions' forums.
"It has been an honour to have worked with the AMOC and AACC professionals to organize the program for the 58th Annual Meeting. I have been a member since 1990 and in that time watched molecular pathology grow both within the AACC and become a mainstay of laboratory medicine," stated Dr. Farkas, VP Clinical Diagnostics of ChondroGene. "I joined ChondroGene from my long career in hospital-based DNA labs because of the potential for our Sentinel Principle(TM) to do for molecular diagnostics this decade what PCR did in the last decade. As the field matures, AACC promises to continue to be a leader in providing education about molecular diagnostics and gene expression profiling."
AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and clinical laboratory science disciplines. Founded in 1948, the society has 9,500 members and is headquartered in Washington, DC. For additional information go to www.AACC.org.
ChondroGene is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. ChondroGene is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on ChondroGene, visit www.chondrogene.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release.ChondroGene Limited
CONTACT: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x234,email@example.com; Bruno Maruzzo, Corporate Development, (416)650-0060 x237, firstname.lastname@example.org